CA2876824C - Nucleic acids for treatment of allergies - Google Patents

Nucleic acids for treatment of allergies Download PDF

Info

Publication number
CA2876824C
CA2876824C CA2876824A CA2876824A CA2876824C CA 2876824 C CA2876824 C CA 2876824C CA 2876824 A CA2876824 A CA 2876824A CA 2876824 A CA2876824 A CA 2876824A CA 2876824 C CA2876824 C CA 2876824C
Authority
CA
Canada
Prior art keywords
nucleic acid
acid molecule
allergen
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2876824A
Other languages
English (en)
French (fr)
Other versions
CA2876824A1 (en
Inventor
William Hearl
Teri Heiland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomic Therapeutics Inc
Original Assignee
Immunomic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomic Therapeutics Inc filed Critical Immunomic Therapeutics Inc
Publication of CA2876824A1 publication Critical patent/CA2876824A1/en
Application granted granted Critical
Publication of CA2876824C publication Critical patent/CA2876824C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CA2876824A 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies Active CA2876824C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/042552 WO2013187906A1 (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies

Publications (2)

Publication Number Publication Date
CA2876824A1 CA2876824A1 (en) 2013-12-19
CA2876824C true CA2876824C (en) 2020-07-21

Family

ID=49758576

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2876824A Active CA2876824C (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies

Country Status (20)

Country Link
US (3) US9744230B2 (https=)
EP (2) EP3808361A1 (https=)
JP (1) JP5807994B2 (https=)
KR (2) KR102107646B1 (https=)
CN (2) CN104519896B (https=)
AU (3) AU2012382406B2 (https=)
BR (1) BR112014031327B1 (https=)
CA (1) CA2876824C (https=)
CY (1) CY1123769T1 (https=)
DK (1) DK2861240T3 (https=)
ES (1) ES2831723T3 (https=)
HR (1) HRP20201815T1 (https=)
HU (1) HUE052481T2 (https=)
IL (4) IL236174B (https=)
LT (1) LT2861240T (https=)
PL (1) PL2861240T3 (https=)
PT (1) PT2861240T (https=)
RS (1) RS61098B1 (https=)
SI (1) SI2861240T1 (https=)
WO (1) WO2013187906A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160185831A1 (en) * 2011-06-14 2016-06-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
EP3808361A1 (en) 2012-06-15 2021-04-21 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
US11096994B2 (en) 2012-10-30 2021-08-24 Aravax Pty Ltd Immunotherapeutic molecules and uses thereof
CN121714673A (zh) 2013-09-25 2026-03-24 阿拉沃克斯有限公司 新型免疫治疗组合物及其用途
US20170304432A1 (en) * 2014-06-23 2017-10-26 Immunomic Therapeutics, Inc. Nucleic acids for treatment of peanut allergies
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
HUE053674T2 (hu) 2015-12-23 2021-07-28 Medigene Immunotherapies Gmbh Antigén-specifikus TCR receptorok új generációja
CN110418650A (zh) * 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
KR102637960B1 (ko) * 2017-04-22 2024-02-21 이뮤노믹 쎄라퓨틱스, 인크. 개선된 lamp 구축물
US12358962B2 (en) * 2017-05-02 2025-07-15 Immunomic Therapeutics, Inc. Lamp constructs comprising cancer antigens
NZ760884A (en) 2017-07-18 2023-05-26 Nestle Sa Methods for making mixed allergen compositions
KR102031845B1 (ko) * 2018-04-06 2019-10-15 주식회사 에스엘에스바이오 신규한 면역글로불린 e의 에피토프, 그와 결합하는 항체 및 상기 항체를 포함하는 시료 중 면역글로불린 e를 분석하기 위한 키트
US20210163957A1 (en) * 2018-05-11 2021-06-03 Astellas Pharma Inc. Nucleic acid for treating mite allergy
CA3099505A1 (en) * 2018-05-11 2019-11-14 Astellas Pharma Inc. Nucleic acid for treating crustacean allergy
US12398195B2 (en) 2018-05-15 2025-08-26 Immunomic Therapeutics, Inc. Lamp constructs comprising allergens
CN113507844A (zh) 2019-01-23 2021-10-15 前品牌股份有限公司 制备混合型过敏原组合物的方法
US12576123B2 (en) 2019-03-13 2026-03-17 Psomagen, Inc. Epitope-based approach for allergy treatments and inhibitors for Crohn's disease
JP2024517463A (ja) * 2021-05-04 2024-04-22 ソヴィダ ソリューションズ リミテッド ニコチンアミドアデニンジヌクレオチド（ｎａｄ）組成物、それらの製造方法、及びそれらの使用方法
CA3228426A1 (en) * 2021-08-06 2023-02-09 Kao Corporation Nucleic acid structure utilizing snare
FI131854B1 (en) 2023-05-29 2026-01-12 Onni Biotechnologies Oy Modified natural killer cells with enhanced cytotoxic activity and greater survival

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD335810S (en) 1990-07-02 1993-05-25 Dick-Ming Asien Handle for luggage or similar article
US6982326B1 (en) 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
US6090386A (en) 1991-07-12 2000-07-18 Griffith; Irwin J. T cell peptides of the CRX JII allergen
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
WO1994011512A2 (en) * 1992-11-12 1994-05-26 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
JP3649460B2 (ja) 1993-11-05 2005-05-18 明治乳業株式会社 スギ花粉アレルゲンＣｒｙ ｊ ＩＩエピトープ
GB9516760D0 (en) 1995-08-16 1995-10-18 Sandoz Ltd Organic compounds
AU729836B2 (en) 1995-12-29 2001-02-08 University Of Arkansas, The Peanut allergens and methods
JP3734040B2 (ja) 1996-06-14 2006-01-11 明治乳業株式会社 Ｔ細胞エピトープペプチド
WO2001076642A1 (en) * 2000-04-07 2001-10-18 The Regents Of The University Of California Synergistic improvements to polynucleotide vaccines
AU2002306850A1 (en) 2001-03-16 2002-10-03 Panacea Pharmaceuticals Methods and reagents for decreasing clinical reaction to allergy
DK1385538T3 (da) * 2001-04-05 2013-04-29 Univ Johns Hopkins Kimære vacciner omfattende det lumenale domæne fra LAMP-1 eller LAMP-2
US20060003148A1 (en) 2004-06-30 2006-01-05 Zwynenburg James L Interlocking polymeric foam floor underlayment and process for making
US20060216315A1 (en) * 2005-03-16 2006-09-28 Yoo Tai J Cockroach allergen gene expression and delivery systems and uses
WO2006138435A2 (en) 2005-06-16 2006-12-28 Mount Sinai School Of Medicine Methods for enhancing immune responses
US7566456B2 (en) 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
EP1932538A4 (en) * 2005-08-25 2009-10-21 Taiho Pharmaceutical Co Ltd BIODEGRADABLE NANOTEHICLES WITH IMMOBILIZED OR CAPACITATED T-CELL-RECOGNIZABLE EPITOPEPEPID
US20080006554A1 (en) 2006-07-07 2008-01-10 Medtronic Vascular, Inc. Packaging assembly for a catheter
EP2042193A1 (en) * 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
EA023912B1 (ru) * 2008-09-10 2016-07-29 АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ Лечение воспалительных состояний
EP3808361A1 (en) * 2012-06-15 2021-04-21 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
CN110418650A (zh) * 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
KR102637960B1 (ko) * 2017-04-22 2024-02-21 이뮤노믹 쎄라퓨틱스, 인크. 개선된 lamp 구축물

Also Published As

Publication number Publication date
IL270260B (en) 2020-08-31
CN104519896A (zh) 2015-04-15
IL270261B (en) 2021-03-25
EP2861240B1 (en) 2020-09-09
WO2013187906A1 (en) 2013-12-19
IL270262A (en) 2019-12-31
KR102107646B1 (ko) 2020-05-08
US20160271245A1 (en) 2016-09-22
US10072053B2 (en) 2018-09-11
CN107937423A (zh) 2018-04-20
AU2012382406B2 (en) 2017-12-07
EP3808361A1 (en) 2021-04-21
LT2861240T (lt) 2021-01-25
AU2018200625A1 (en) 2018-02-15
HRP20201815T1 (hr) 2021-02-19
CA2876824A1 (en) 2013-12-19
ES2831723T3 (es) 2021-06-09
PL2861240T3 (pl) 2021-07-05
SI2861240T1 (sl) 2021-04-30
DK2861240T3 (da) 2020-09-28
US20220081474A1 (en) 2022-03-17
EP2861240A4 (en) 2016-03-16
BR112014031327A2 (pt) 2017-06-27
JP5807994B2 (ja) 2015-11-10
CY1123769T1 (el) 2022-05-27
US20180009857A1 (en) 2018-01-11
AU2012382406A2 (en) 2015-04-16
KR102386481B1 (ko) 2022-04-14
PT2861240T (pt) 2020-11-09
IL236174B (en) 2019-11-28
RS61098B1 (sr) 2020-12-31
AU2019250227B2 (en) 2021-10-21
JP2015521467A (ja) 2015-07-30
AU2012382406A1 (en) 2014-12-18
CN104519896B (zh) 2017-11-10
IL236174A0 (en) 2015-01-29
KR20200047792A (ko) 2020-05-07
BR112014031327B1 (pt) 2022-02-01
US9744230B2 (en) 2017-08-29
EP2861240A1 (en) 2015-04-22
HUE052481T2 (hu) 2021-04-28
KR20150032286A (ko) 2015-03-25
AU2019250227A1 (en) 2019-11-07
AU2018200625B2 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
AU2019250227B2 (en) Nucleic acids for treatment of allergies
US20190298821A1 (en) Nucleic Acids for Treatment of Peanut Allergies
JP5399895B2 (ja) ワクチン担体
US20160185831A1 (en) Nucleic acids for treatment of allergies
JP6353510B2 (ja) アレルギー治療のための核酸
JP6088584B2 (ja) アレルギー治療のための核酸
HK1253363A1 (zh) 用於治疗变态反应的核酸
BRPI0712421B1 (pt) Proteína de fusão hipoalergênica derivada de phl p 5

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170609

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250606

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250606